{
    "clinical_study": {
        "@rank": "168199", 
        "arm_group": {
            "arm_group_label": "MLN9708", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is an open-label, multicenter, phase 2 study to evaluate the efficacy and safety of\n      oral MLN9708 in adult patients with follicular lymphoma (FL) that is relapsed and/or\n      refractory to prior treatment."
        }, 
        "brief_title": "Phase 2 Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma", 
        "completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Follicular Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Follicular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female patients 18 years or older\n\n          -  Patients must have a pathologically confirmed diagnosis of non-Hodgkin lymphoma (NHL)\n             (for the lead-in dose-finding phase) and FL (for phase 2)\n\n          -  Patients must have radiographically or clinically measurable disease\n\n          -  Patients must be relapsed and/or refractory after at least 1 prior therapy (excluding\n             radiation) with documented progressive disease at the time of enrollment\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n\n          -  Female patients who are post menopausal, surgically sterile, or agree to practice 2\n             effective methods of contraception or agree to practice true abstinence\n\n          -  Male patients who agree to practice effective barrier contraception or agree to\n             practice true abstinence\n\n          -  Voluntary written consent\n\n          -  Suitable venous access\n\n          -  Appropriate clinical laboratory values as defined in the protocol\n\n          -  Recovered from toxicities of prior anticancer therapy\n\n          -  If the trial proceeds to the second step on the basis of the tandem 2-step design,\n             patients must be confirmed PSMB1 positive at the central laboratory before treatment\n\n        Exclusion Criteria\n\n          -  Peripheral neuropathy that is greater or equal to Grade 2 or Grade 1 with pain\n\n          -  Female patients who are lactating and breastfeeding or have a positive serum\n             pregnancy test during the Screening period\n\n          -  Autologous stem cell transplant within 6 months before Day 1 of Cycle 1, or prior\n             allogeneic stem cell transplant at any time\n\n          -  Major surgery within 14 days before the first dose of study drug\n\n          -  Infection requiring systemic antibiotic therapy or other serious infection within 14\n             days before the first dose of study drug\n\n          -  Comorbid systemic illnesses or other severe concurrent disease that, in the judgment\n             of the investigator, would make the patient inappropriate for entry into this study\n             or interfere significantly with the proper assessment of safety and toxicity of the\n             prescribed regimens\n\n          -  Evidence of current uncontrolled cardiovascular conditions including uncontrolled\n             hypertension, severe uncontrolled ventricular arrhythmias, unstable angina, New York\n             Heart Association (NYHA) Class III or IV cardiac disease, or myocardial infarction\n             within the past 6 months\n\n          -  Diarrhea > Grade 1 on the basis of the NCI CTCAE categorization\n\n          -  Systemic antineoplastic (including glucocorticoids > the equivalent of 15 mg of\n             prednisone daily), experimental, or radiation therapy within 21 days before the first\n             dose of study drug\n\n          -  Prior treatment with rituximab or other unconjugated antibody treatment within 42\n             days (21 days if clear evidence of progressive disease or immediate treatment is\n             mandated)\n\n          -  Treatment with radioimmunoconjugates or toxin immunoconjugates within 12 weeks before\n             the first dosing of study treatment\n\n          -  Systemic treatment with strong inhibitors of CYP1A2 or CYP3A, or strong CYP3A\n             inducers within 14 days before the first dose of MLN9708\n\n          -  Ongoing systemic therapy with corticosteroids\n\n          -  Central nervous system (CNS) involvement that is clinically uncontrolled or newly\n             diagnosed in the last 4 months\n\n          -  Ongoing or active systemic viral infection, known human immunodeficiency virus(HIV)\n             positive, known active hepatitis B virus or known active hepatitis C virus\n\n          -  Diagnosed or treated for another malignancy within 2 years before study enrollment or\n             previously diagnosed with another malignancy and have any evidence of residual\n             disease with the exception of nonmelanoma skin cancer or any completely resected\n             carcinoma in situ\n\n          -  Platelet transfusions within 3 days before the 1st dose of study drug\n\n          -  Inability to swallow capsules, or inability or unwillingness to avoid taking anything\n             by mouth except for water and prescribed medication for 2 hours before and 1 hour\n             after dose of MLN9708\n\n          -  Known allergy to boron or excipients in the formulation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "58", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01939899", 
            "org_study_id": "C16017", 
            "secondary_id": "2013-002302-32"
        }, 
        "intervention": {
            "arm_group_label": "MLN9708", 
            "description": "Each 28-day treatment cycle will include oral administration of MLN9708 on Days 1, 8, and 15 followed by a rest period of 13 days.", 
            "intervention_name": "MLN9708", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "MLN9708", 
            "Lymphoma"
        ], 
        "lastchanged_date": "November 19, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nashville", 
                    "country": "United States", 
                    "state": "Tennessee", 
                    "zip": "37203"
                }, 
                "name": "Sarah Cannon Research Institute"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Multicenter, Phase 2 Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma", 
        "overall_contact": {
            "email": "medical@mlnm.com", 
            "last_name": "For an updated listing of recruitment sites contact: Millennium Medical and Drug Information Center", 
            "phone": "1-877-674-3784"
        }, 
        "overall_official": {
            "affiliation": "Millennium Pharmaceuticals, Inc.", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "European Union: European Medicines Agency", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall Response (Complete Response (CR) + Partial Response(PR)) Rate (ORR)", 
            "safety_issue": "No", 
            "time_frame": "Time from the start of treatment to the occurrence of disease progression, unacceptable toxicities, or discontinuation of study due to any other reasons (up to approximately 24 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01939899"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Recommended Phase 2 Dose (RP2D)", 
                "safety_issue": "No", 
                "time_frame": "Approximately 8 months after dosing the first patient"
            }, 
            {
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Up to a total of 24 months after first dose or until disease progression, withdrawal from study, or death"
            }, 
            {
                "measure": "Rate of Disease Control", 
                "safety_issue": "No", 
                "time_frame": "Time from the start of treatment to the occurrence of disease progression, unacceptable toxicities, or discontinuation of study due to any other reasons (up to approximately 24 months)"
            }, 
            {
                "measure": "Time to Response (TTR)", 
                "safety_issue": "No", 
                "time_frame": "Time from the date of registration to the date at which the patient's objective status is first noted to be a CR or PR (assessed up to approximately 24 months)"
            }, 
            {
                "measure": "Duration of Response (DOR)", 
                "safety_issue": "No", 
                "time_frame": "Time from the date at which the patient's objective status is first noted to be a CR or PR to the earliest date progression is documented (assessed up to approximately 24 months)"
            }, 
            {
                "measure": "Response rates in FL patients positive versus negative for the proteasome subunit beta type-1 (PSMB1) polymorphic marker", 
                "safety_issue": "No", 
                "time_frame": "Time from the start of treatment to the occurrence of disease progression, unacceptable toxicities, or discontinuation of study due to any other reasons (up to approximately 24 months)"
            }, 
            {
                "measure": "Number of participants with Adverse Events (AE) or Serious Adverse Events (SAE)", 
                "safety_issue": "Yes", 
                "time_frame": "Signing of informed consent through 30 days after last dose"
            }, 
            {
                "measure": "Plasma PK parameters including Maximum Concentration (Cmax), Single-dose time to reach maximum plasma concentration (Tmax), Area under the plasma concentration versus time curve (AUC) from zero to time of last quantifiable plasma concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "Days 1-3, 5, 8, 15-17, 19 and 22 during Cycle 1 and Day 1 during Cycles 2-4 of each lead-in dose finding cohort"
            }
        ], 
        "source": "Millennium Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Millennium Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}